Home » Topics » BioWorld MedTech

BioWorld MedTech
RSS

APPOINTMENTS AND ADVANCEMENTS

Feb. 3, 1992

GENELABS DEAL FOR ANTI-CANCER DRUG

Feb. 3, 1992

FDA PANEL TURNS DOWN U.S. BIO'S ETHYOL

Feb. 3, 1992

ZYNAXIS RAISES $22.5 MILLION IN IPO

Jan. 31, 1992

IMMUNEX TO SWAP DRUGS WITH BRISTOL-MYERS

Jan. 31, 1992

POSITIVE RESULTS FROM AIDS VACCINE TRIAL

Jan. 31, 1992

GENSIA TO EVALUATE EYE TREATMENT

Jan. 31, 1992

ANALYST DOWNGRADES U.S. BIOSCIENCE

Jan. 31, 1992

CORVAS IPO RAISES $36 MILLION

Jan. 31, 1992

IMMUNOMEDICS RAISES $28 MILLION

Jan. 31, 1992

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...